1620 Investment Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

1620 Investment Advisors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,590	Closed	-$32K	–	692
2026 Q1	$32K	Hold	1,590	–	–	0.02%	346
2025 Q4	$25.7K	Hold	1,590	–	–	0.02%	368
2025 Q3	$19.4K	Hold	1,590	–	–	0.01%	391
2025 Q2	$18K	Hold	1,590	–	–	0.01%	406
2025 Q1	$18.3K	Hold	1,590	–	–	0.01%	390
2024 Q4	$13.5K	Hold	1,590	–	–	0.01%	427
2024 Q3	$18.4K	Hold	1,590	–	–	0.01%	410
2024 Q2	$18.7K	Buy	+1,590	New	+$18.6K	0.01%	400

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

1620 Investment Advisors's KALV Position: Q2 2026 in Review

1620 Investment Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,590 shares — an estimated $32K sold.

1620 Investment Advisors first reported a position in KALV in Q2 2024 and held it in 8 quarters. The position peaked at $32K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

1620 Investment Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
1620 Investment Advisors sold 1,590 KalVista Pharmaceuticals shares in Q2 2026, an estimated $32K.
1620 Investment Advisors first reported a position in KalVista Pharmaceuticals in Q2 2024 and held it in 8 quarters.
1620 Investment Advisors's KalVista Pharmaceuticals position peaked at $32K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.